Psychiatrist warns profit motives are stalling breakthroughs in mental health drugs
Dr. Gabriella Gobbi, a prominent psychiatrist at McGill University, has criticised how profit-driven models are hampering progress in psychiatric drug research. Her warnings come alongside groundbreaking work in molecular neuroscience, where her team's discoveries have shaped both clinical practice and public policy.
Dr. Gobbi's research spans cannabinoids, melatonin receptors, and the neurobiology of psychedelic substances. Since 2013, her team has investigated how these compounds interact with brain pathways, particularly serotonin receptors linked to depression. Their preclinical studies have identified potential therapeutic mechanisms, though no clinical trials on psychedelics have been led by her group.
Her lab's work on the melatonin MT2 receptor led to an MT2-selective partial agonist now under clinical review. Yet, she highlights a persistent challenge: early-stage discoveries, often publicly funded, struggle to advance when venture capital demands high returns. This bottleneck, she argues, prioritises financial gain over patient needs. Beyond research, Dr. Gobbi pushes for systemic change. She calls for mentorship programmes to nurture scientific talent and structural reforms to address gender inequities in academia. Her critique extends to harassment and systemic barriers that limit opportunities for women in science. Her influence reaches beyond the lab. Findings on cannabinoids have informed Canada's cannabis regulations, demonstrating how fundamental research can guide policy. Still, she insists that innovation must be guided by ethical frameworks centred on patient welfare, not market pressures.
Dr. Gobbi's dual focus on scientific discovery and systemic reform underscores the need for a more equitable research environment. Her team's work continues to bridge gaps between biology and clinical care, but she warns that lasting progress depends on aligning financial incentives with public health goals. Without reform, promising treatments may remain out of reach for those who need them most.
